FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892210080> ?p ?o ?g. }

• W2892210080 endingPage "2685" @default.
• W2892210080 startingPage "2685" @default.
• W2892210080 abstract "Background: Oxidant stress plays a key role in the development of chronic kidney disease (CKD). Experimental CKD leads to accumulation of uremic toxins (UT) in the circulation resulting in increased ROS production, which in turn, is known to activate the Na/K-ATPase/ROS amplification loop. Studies in a murine model of obesity have shown that increased oxidative stress in plasma is due to increased ROS and cytokine production from dysfunctional adipocytes. Therefore, we hypothesized that adipocytes exposed to UTs will activate the Na/K-ATPase oxidant amplification loop causing redox imbalance and phenotypic alterations in adipocytes. We also aimed to demonstrate that the Na/K-ATPase signaling antagonist, pNaKtide, attenuates these pathophysiological consequences. Methods: In the first set of experiments, 3T3-L1 murine pre-adipocytes were treated with varying concentrations of UTs, indoxyl sulfate (IS) (50, 100 and 250 µM) and p-cresol (50, 100 and 200 µM), with or without pNaKtide (0.7 µM) for five days in adipogenic media, followed by Oil Red O staining to study adipogenesis. RT-PCR analysis was performed to study expression of adipogenic, apoptotic and inflammatory markers, while DHE staining evaluated the superoxide levels in UT treated cells. In a second set of experiments, visceral fat was obtained from the West Virginian population. MSCs were isolated and cultured in adipogenic media for 14 days, which was treated with indoxyl sulfate (0, 25, 50 and 100 µM) with or without pNaKtide (1 µM). MSC-derived adipocytes were evaluated for morphological and molecular analysis of the above markers. Results: Our results demonstrated that 3T3-L1 cells and MSCs-derived adipocytes, treated with UTs, exhibited a significant decrease in adipogenesis and apoptosis through activation of the Na/K-ATPase/ROS amplification loop. The treatment with pNaKtide in 3T3-L1 cells and MSC-derived adipocytes negated the effects of UTs and restored cellular redox in adipocytes. We noted a varying effect of pNaKtide, in adipocytes treated with UTs, on inflammatory markers, adipogenic marker and superoxide levels in 3T3-L1 cells and MSC-derived adipocytes. Conclusions: This study demonstrates for the first time that the Na/K-ATPase/ROS amplification loop activated by elevated levels of UTs has varying effect on phenotypic alterations in adipocytes in various in vitro models. Thus, we propose that, if proven in humans, inhibition of Na/K-ATPase amplification of oxidant stress in CKD patients may ultimately be a novel way to combat adipocyte dysfunction and metabolic imbalance in these patients." @default.
• W2892210080 created "2018-09-27" @default.
• W2892210080 creator A5005428451 @default.
• W2892210080 creator A5008556766 @default.
• W2892210080 creator A5019242155 @default.
• W2892210080 creator A5039402787 @default.
• W2892210080 creator A5044075001 @default.
• W2892210080 creator A5048071483 @default.
• W2892210080 creator A5051060833 @default.
• W2892210080 creator A5060542716 @default.
• W2892210080 creator A5061489016 @default.
• W2892210080 creator A5066250484 @default.
• W2892210080 creator A5072802588 @default.
• W2892210080 creator A5077735587 @default.
• W2892210080 creator A5087375412 @default.
• W2892210080 date "2018-09-10" @default.
• W2892210080 modified "2023-09-25" @default.
• W2892210080 title "Uremic Toxins Activates Na/K-ATPase Oxidant Amplification Loop Causing Phenotypic Changes in Adipocytes in In Vitro Models" @default.
• W2892210080 cites W1875533420 @default.
• W2892210080 cites W1963705367 @default.
• W2892210080 cites W1969084842 @default.
• W2892210080 cites W1989298394 @default.
• W2892210080 cites W2014221097 @default.
• W2892210080 cites W2029785070 @default.
• W2892210080 cites W2033792510 @default.
• W2892210080 cites W2034591847 @default.
• W2892210080 cites W2040137092 @default.
• W2892210080 cites W2064893304 @default.
• W2892210080 cites W2098293941 @default.
• W2892210080 cites W2114467894 @default.
• W2892210080 cites W2117261670 @default.
• W2892210080 cites W2124821727 @default.
• W2892210080 cites W2139770322 @default.
• W2892210080 cites W2140035060 @default.
• W2892210080 cites W2169896560 @default.
• W2892210080 cites W2178568888 @default.
• W2892210080 cites W2179419395 @default.
• W2892210080 cites W2276593581 @default.
• W2892210080 cites W2416791589 @default.
• W2892210080 cites W2486170751 @default.
• W2892210080 cites W2488868277 @default.
• W2892210080 cites W2493199848 @default.
• W2892210080 cites W2513420589 @default.
• W2892210080 cites W2528486210 @default.
• W2892210080 cites W2599558286 @default.
• W2892210080 cites W2619222443 @default.
• W2892210080 cites W2808739390 @default.
• W2892210080 cites W2819651345 @default.
• W2892210080 cites W2886076351 @default.
• W2892210080 cites W4236646947 @default.
• W2892210080 cites W788929558 @default.
• W2892210080 doi "https://doi.org/10.3390/ijms19092685" @default.
• W2892210080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6164729" @default.
• W2892210080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30201874" @default.
• W2892210080 hasPublicationYear "2018" @default.
• W2892210080 type Work @default.
• W2892210080 sameAs 2892210080 @default.
• W2892210080 citedByCount "17" @default.
• W2892210080 countsByYear W28922100802019 @default.
• W2892210080 countsByYear W28922100802020 @default.
• W2892210080 countsByYear W28922100802021 @default.
• W2892210080 countsByYear W28922100802022 @default.
• W2892210080 countsByYear W28922100802023 @default.
• W2892210080 crossrefType "journal-article" @default.
• W2892210080 hasAuthorship W2892210080A5005428451 @default.
• W2892210080 hasAuthorship W2892210080A5008556766 @default.
• W2892210080 hasAuthorship W2892210080A5019242155 @default.
• W2892210080 hasAuthorship W2892210080A5039402787 @default.
• W2892210080 hasAuthorship W2892210080A5044075001 @default.
• W2892210080 hasAuthorship W2892210080A5048071483 @default.
• W2892210080 hasAuthorship W2892210080A5051060833 @default.
• W2892210080 hasAuthorship W2892210080A5060542716 @default.
• W2892210080 hasAuthorship W2892210080A5061489016 @default.
• W2892210080 hasAuthorship W2892210080A5066250484 @default.
• W2892210080 hasAuthorship W2892210080A5072802588 @default.
• W2892210080 hasAuthorship W2892210080A5077735587 @default.
• W2892210080 hasAuthorship W2892210080A5087375412 @default.
• W2892210080 hasBestOaLocation W28922100801 @default.
• W2892210080 hasConcept C122927707 @default.
• W2892210080 hasConcept C126322002 @default.
• W2892210080 hasConcept C134018914 @default.
• W2892210080 hasConcept C185592680 @default.
• W2892210080 hasConcept C202751555 @default.
• W2892210080 hasConcept C2776151105 @default.
• W2892210080 hasConcept C2780806160 @default.
• W2892210080 hasConcept C2908647359 @default.
• W2892210080 hasConcept C48349386 @default.
• W2892210080 hasConcept C54355233 @default.
• W2892210080 hasConcept C55493867 @default.
• W2892210080 hasConcept C71924100 @default.
• W2892210080 hasConcept C74864618 @default.
• W2892210080 hasConcept C86803240 @default.
• W2892210080 hasConcept C99454951 @default.
• W2892210080 hasConceptScore W2892210080C122927707 @default.
• W2892210080 hasConceptScore W2892210080C126322002 @default.
• W2892210080 hasConceptScore W2892210080C134018914 @default.
• W2892210080 hasConceptScore W2892210080C185592680 @default.
• W2892210080 hasConceptScore W2892210080C202751555 @default.

• next